Cytosorbents (CTSO) Receivables (2011 - 2026)

Cytosorbents has reported Receivables for 16 years, with the latest figure at $14.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 3.84% year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (up 3.84% YoY), and the FY2025 full-year result was $14.7 million, up 13.58% from the prior year.
• Receivables for Q1 2026 stood at $14.1 million, down from $14.7 million in the prior quarter.
• The five-year high for Receivables was $14.7 million in Q4 2025, with the low at $7.7 million in Q1 2022.
• Historically, Receivables has averaged $11.7 million across 5 years, with a median of $11.7 million in 2024.
• The largest YoY upside for Receivables was 26.09% in 2022 against a maximum downside of 0.62% in 2022.
• Cytosorbents' Receivables stood at $9.5 million in 2022, then increased by 19.71% to $11.4 million in 2023, then rose by 13.76% to $12.9 million in 2024, then grew by 13.58% to $14.7 million in 2025, then retreated by 4.25% to $14.1 million in 2026.
• The last three Receivables figures came in at $14.1 million (Q1 2026), $14.7 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.